Abstract
In this study, we have modified 4-hydroxy-pyran-2-ones, especially introduced heteroatoms (S or O) into the substituents, and detected their interactions with the binding pockets of HIV-1 protease (PR). The results indicated that the ethoxyl groups at C-2′ and C-5′ of the phenyl ring could enhance the affinities to the S 1 ′ and S 2 ′ pockets and improve the inhibitory activities. The most potent compound 10f with an IC50 of 3.5 nM in enzymatic assay also exhibited good antiviral activity at the cellular level; it exhibited an EC50 value of 2.9 μM in Simian immunodeficiency virus-infected CEM cells and suppressed the PR activity in 293T cells using western blot analysis.
Similar content being viewed by others
References
Chien AI, Liao WH, Yang DM, Wang CT (2006) A domain directly C-terminal to the major homology region of human immunodeficiency type 1 capsid protein plays a crucial role in directing both virus assembly and incorporation of Gag-Pol. Virology 348:84–95
Huang XQ, Xu LS, Luo XM, Fan KN, Ji RY, Pei G, Chen KX, Jiang HL (2002) Elucidating the inhibiting mode of AHPBA derivatives against HIV-1 protease and building predictive 3D-QSAR models. J Med Chem 45:333–343
Huff JR (1991) HIV protease: a novel chemotherapeutic target for AIDS. J Med Chem 34:2305–2314
Lebon F, Ledecq M (2000) Approaches to the design of effective HIV-1 protease inhibitors. Curr Med Chem 7:455–477
Leung D, Abbenante G, Fairlie DP (2000) Protease inhibitors: current status and future prospects. J Med Chem 43:305–341
Lunney EA, Hagen SE, Domagala JM, Humblet C, Kosinski J, Tait BD, Warmus JS, Wilson M, Ferguson D, Hupe D, Tummino PJ, Baldwin ET, Bhat TN, Liu B, Erickson JW (1994) A novel nonpeptide HIV-1 protease inhibitor: elucidation of the binding mode and its application in the design of related analogs. J Med Chem 37:2664–2677
Mahlknecht U, Deng C, Lu MC, Greenough TC, Sullivan JL, O’Brien WA, Herbein G (2000) Resistance to apoptosis in HIV-infected CD4+ T lymphocytes is mediated by macrophages: role for Nef and immune activation in viral persistence. J Immunol 165:6437–6446
Meek TD (1992) Inhibitors of HIV-1 protease. J Enzym Inhib 6:65–98
Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19:1639–1662
Nashed NT, Louis JM, Sayer JM, Wondrak EM, Mora PT, Oroszlan S, Jerina DM (1989) Continuous spectrophotometric assay for retroviral protease of HIV-1 and AMV. Biochem Biophy Res Commun 163:1079–1085
Peter M, Knudsen LB, Wiberg FC, Carr RD (1998) Discovery and structure–activity relationship of the first non-peptide competitive human glucagon receptor antagonists. J Med Chem 41:5150–5157
Redshaw S (1994) Inhibitors of HIV proteinase. Exp Opin Invest Drugs 3:273–286
Romines KR, Chrusciel RA (1995) 4-Hydroxypyrones and related templates as nonpeptidic HIV protease inhibitors. Curr Med Chem 2:825–838
Seshadri R, Pegg WJ, Israel M (1981) Reaction of halomethyl ketones with thiols and selenols: substitution vs reduction. J Org Chem 46:2596–2598
Skulnick HI, Johnson PD, Howe W, Tomich PK, Chong KT, Watenpaugh KD, Janakiraman MN, Hinshaw RR, Zipp GL, Ruwart MJ, Schwende FJ, Zhong WZ, Padbury GE, Dalga RJ, Shiou L, Possert PL, Rush BD, Wilkinson KF, Howard GM, Toth LN, Williams MG, Kakuk TJ, Cole SL, Zaya RM, Lovasz KD, Morris JK, Romines KR, Thaisrivongs S, Aristoff PA (1995) Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors. J Med Chem 38:4968–4971
Sun CL, Pang RF, Zhang H, Yang M (2005) Design, synthesis, and biological evaluation of novel 4-hydroxypyrone derivatives as HIV-1 protease inhibitors. Bioorg Med Chem Lett 15:3257–3262
Tait BD, Domagala JM, Ellsworth EL, Gajda C, Hagen SE, Hamilton H, Vara Prasad JVN, Ferguson D, Graham N, Hupe D, Nouhan C, Tummino PJ, Humblet C, Lunney EA, Pavlovsky A, Rubin RJ, Baldwin ET, Bhat TN, Erickson JW, Gulnik S, Liu BS (1997) 4-Hydroxy-5, 6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease. J Med Chem 40:3781–3792
Thaisrivongs S (1994) HIV protease inhibitors. Annu Rep Med Chem 29:133–144
Thaisrivongs S, Romero DL, Tommasi RA, Janakiraman MN, Strohbach JW, Turner SR, Biles C, Morge RR, Johnson PD, Aristoff PA, Tomich PK, Lynn JC, Horng MM, Chong KT, Hinshaw RR, Howe WJ, Finzel BC, Watenpaugh KD (1996) Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors. J Med Chem 39:4630–4642
Tummino PJ, Vara Prasad JVN, Ferguson D, Nouhan C, Graham N, Domagala JM, Ellsworth E, Gajda C, Hagen SE, Lunney EA, Para KS, Tait BD, Pavlovsky A, Erickson JW, Gracheck S, McQuade TJ, Hupe DJ (1996) Discovery and optimization of nonpeptide HIV-1 protease inhibitors. Bioorg Med Chem 4:1401–1410
Vara Prasad JVN, Boye FE, Domagala JM, Ellsworth EL, Gajda C, Hamilton HW, Hagen SE, Markoski LJ, Steinbaugh BA, Tait BD, Humblet C, Lunney EA, Pavlovsky A, Rubin JR, Ferguson D, Graham N, Holler T, Hupe D, Nouhan C, Tummino PJ, Urumov A, Zeikus E, Zeikus G, Gracheck SJ, Saunders JM, VanderRoest S, Brodfuehrer J, Iyer K, Sinz M, Gulnik SV (1999) Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor. Bioorg Med Chem 7:2775–2800
Wang TC, Lee KH, Chen YL, Liou SS (1998) Synthesis and anticancer evaluation of certain γ-aryloxymethyl-α-methylene-γ-phenyl-γ-butyrolactones. Bioorg Med Chem Lett 8:2773–2776
West ML, Fairlie DP (1995) Targeting HIV-1 PR: a test of drug-design methodologies. Trends Pharmacol Sci 16:67–75
Acknowledgment
This study was supported by the National Science Foundation of China (No. 30670415).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
He, M., Yang, N., Sun, C. et al. Modification and biological evaluation of novel 4-hydroxy-pyrone derivatives as non-peptidic HIV-1 protease inhibitors. Med Chem Res 20, 200–209 (2011). https://doi.org/10.1007/s00044-010-9307-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-010-9307-4